Researchers at Korea University College of Medicine have developed a liquid biopsy method that can detect cancer mutations present in very low frequencies from all cell-free DNA in a typical blood sample. The ultrasensitive method, called MUTE-Seq, uses FnCas9-AF2, an engineered high-fidelity CRISPR enzyme that depletes wild-type DNA in the sample before sequencing allowing for circulating tumor DNA (ctDNA) detection below 0.1% of total cfDNA, exceeding current detection limits. Details of this new approach are published in the journal Advanced Materials .

“Our findings suggest that the MUTE-Seq method has considerable potential for developing diagnosis panels aimed at detecting multiple low-frequency ctDNA for MCED, CDx, or MRD monitoring,” said senior author Junseok W. Hur, MD, Ph

See Full Page